First Pharmaceutical Holdings announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. As a candidate drug for fourth-generation ALK inhibitors, the clinical trial application for SY-12321 capsule single drug in advanced anaplastic lymphoma kinase positive advanced solid tumors was approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.